Geographical variation in incidence of prostate cancer in Sweden: Survey from the National Prostate Cancer Register

Scandinavian Journal of Urology and Nephrology

Volumn 39, Issue 5, 2005, Pages 372-379

  Stattin, Pär ^a   Johansson, Robert ^a   Lodnert, Ronald ^a   Andrén, Ove ^b,c   Bill Axelsson, Anna ^d   Bratt, Ola ^e   Damber, Jan Erik ^f   Hellström, Magnus ^g   Hugosson, Jonas ^f   Lundgren, Rolf ^c,h   Törnblom, Magnus ^g   Varenhorst, Eberhard ⁱ   Johansson, Jan Erik ^j  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b Piteå Hospital   (Sweden)

^c Department of Urology ^*  (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h HELSINGBORG HOSPITAL   (Sweden)

ⁱ LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^j ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Incidence; Prostate cancer; Register; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; ANTIGEN DETECTION; ARTICLE; CANCER CYTODIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; CONTROLLED STUDY; GEOGRAPHICAL VARIATION (SPECIES); HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; SAMPLE SIZE; SCREENING TEST; UNIVERSITY HOSPITAL; URBAN POPULATION;

AGED; HUMANS; INCIDENCE; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RURAL POPULATION; SWEDEN; URBAN POPULATION;

EID: 27944448905     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590500375463     Document Type: Article

References (25)

1. Available from: www.roc.se
2. Sarma AV, Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001. Semin Urol Oncol 2002;20:3-9.
3. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85:60-7.
4. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
5. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Br Med J 2002;325:740.
6. La Rosa F, Stracci F, Minelli L, Mastrandrea V. Epidemiology of prostate cancer in the Umbria region of Italy: evidence of opportunistic screening effects. Urology 2003;62:1040-4.
7. Gavin A, McCarron P, Middleton RJ, Savage G, Catney D, O'Reilly D, et al. Evidence of prostate cancer screening in a UK region. BJU Int 2004;93:730-4.
8. De Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002;97:237-44.
9. Stattin P, Johansson R, Damber JE, Hellstrom M, Hugosson J, Lundgren R, et al. Non-systematic screening for prostate cancer in Sweden. Scand J Urol Nephrol 2003;37:461-5.
10. McNaughton Collins M, Barry MJ, Zietman A, Albertsen PC, Talcott JA, Walker Corkery E, et al. United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region. Urology 2002;60:628-33.
11. Fowler FJ Jr, Bin L, Collins MM, Roberts RG, Oesterling JE, Wasson JH, et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med 1998;104:526-32.
12. Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT. Prostate carcinoma presentation, diagnosis, and staging: an update from the National Cancer Data Base. Cancer 2003;98:1169-78.
13. Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber J-E, Hellström M, et al. The National Prostate Cancer Register in Sweden 1998-2002. Trends in incidence, treatment and survival. Scand J Urol Nephrol 2005;39:117-23.
14. Statistics Sweden. HSI-health care information: register of health care units 2003. Available from: www.scb.se
15. Sandblom G, Mattsson E, Nilsson J, Damber JE, Johansson JE, Lundgren R, et al. Prostate cancer registration in four Swedish regions 1996-differences in incidence, age structure and management. Scand J Urol Nephrol 1999;33: 306-11.
16. Johansson J-E, Abrahamsson P-A, Adami H-O, Adolfsson J, Carlsson P, Damber J-E, et al. Mass screening for prostate cancer. Report No. 126. 1995, ISBN 91-8790-30-J, Stockholm: Swedish Council on Technology Assessment in Health Care (SBU).
17. Ferrini R, Woolf SH. American College of Preventive Medicine practice policy. Screening for prostate cancer in American men. Am J Prev Med 1998;15:81-4.
18. National Health Service. Executive letter on population screening for prostate cancer EL 97, Leeds, UK: NHS; 2002.
19. Aus G, Abbou CC, Pacik D, Schmid HP, van Poppel H, Wolff JM, et al. EAU guidelines on prostate cancer; EAU Working Group on Oncological Urology. Eur Urol 2001;2:97-101.
20. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
21. Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schonitzer D, et al. Screening for prostate cancer: updated experience from the Tyrol study. Curr Urol Rep 2004;5: 220-5.
22. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861-9.
23. Magi-Galluzzi C, Epstein JI. Threshold for diagnosing prostate cancer over time. Hum Pathol 2003;34:1116-8.
24. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100:1397-405.
25. Törnblom M, Eriksson H, Franzén S, Gustafsson O, Lilja H, Norming U, et al. Lead time associated with screening for prostate cancer. Int J Cancer 2004;108:122-9.